NSE · DIVISLAB · Pharmaceuticals
Divis Laboratories Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹2,793 Cr with net profit ₹756 Cr — a 27.07% net margin, versus 23.2% the period before.
Shareholding
As of 2026-06-30
- Promoter51.88%
- Public8.54%
- FII20.2%
- DII19.38%
2,26,324 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1.33× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs · ranked #1 of 30 by market cap · medians across 25 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Divis Laboratories Ltd.(this company) | ₹1,97,110 Cr | 262.27 | 11.74 | 15.32% | 24.32% |
| Acutaas Chemicals Limited | ₹26,999 Cr | 204.95 | 16.33 | 21.54% | 26.6% |
| Neuland Laboratories Ltd. | ₹24,211 Cr | 113.85 | 12.99 | 19.42% | 17.99% |
| Jubilant Pharmova Ltd. | ₹15,346 Cr | 127.61 | 2.15 | 5.62% | 4.84% |
| Aarti Drugs Ltd. | ₹3,727 Cr | 67.49 | 2.41 | 12.58% | 7.6% |
| SMS Pharmaceuticals Ltd. | ₹3,566 Cr | 106.35 | 4.54 | 12.98% | 11.5% |
| Hikal Limited | ₹2,676 Cr | 185.46 | 2.24 | 3.03% | -2.88% |
| Beta Drugs Limited | ₹2,139 Cr | 236.26 | 8.74 | 16.95% | 10.78% |
| NGL Fine Chem Limited | ₹1,984 Cr | 147.14 | 6.03 | 14.62% | 9.59% |
| Fermenta Biotech Ltd. | ₹1,343 Cr | 21.35 | 3.3 | 17.67% | 13.66% |
AI analysis
AI-generated · google/gemini-2.5-flashDivis Laboratories Ltd. (DIVISLAB) is a pharmaceutical sector company with a market capitalization of Rs 194588 Cr. The company reported EPS of 98.81 and a book value of 631.38. Its ROE stands at 15.32% and ROCE at 19.56%.
Positives
- +The company has a strong profit margin of 24.32%.
- +The debt-to-equity ratio is 0, indicating no debt.
- +Promoter holding of 51.88% as of March 31, 2026 suggests significant insider confidence.
- +The ROCE of 19.56% indicates efficient use of capital.
Negatives
- −The P/E ratio is 258.92, which is high.
- −The dividend yield is 41%, but without context of dividend payout, this figure alone is not indicative of overall dividend policy.
- −No quarterly results have been disclosed since March 2026, making it difficult to assess recent performance.
Financial performance
For the fiscal year ending March 2025, Divis Laboratories Ltd. reported revenue of Rs 9712 Cr and a net profit of Rs 2191 Cr. Quarterly revenue for March 2026 was Rs 2831 Cr, with a net profit of Rs 751 Cr. The sequential quarterly revenue for December 2025 was Rs 2604 Cr with a net profit of Rs 583 Cr.
Profitability & returns
The company recorded a profit margin of 24.32%. Return on equity (ROE) was 15.32% and Return on Capital Employed (ROCE) stood at 19.56%. The EPS for the last twelve months was Rs 98.81.
Balance sheet
The debt-to-equity ratio for Divis Laboratories Ltd. is 0, indicating no debt. The book value per share is Rs 631.38.
Ownership & pledges
As of March 31, 2026, promoters held 51.88% of the company's shares. Foreign Institutional Investors (FIIs) held 20.29%, while Domestic Institutional Investors (DIIs) held 19.22%. Public shareholding was 8.61%. There were no promoter pledges reported for the period.
Data as of — price: 2026-07-29 · financials: Mar 26 · shareholding: Jun 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.